References of "Schoneveld, Lauranne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailYKL-40 as a new promising prognostic marker of severity in COVID infection.
Schoneveld, Lauranne ULiege; LADANG, Aurélie ULiege; HENKET, Monique ULiege et al

in Critical care (London, England) (2021), 25(1), 66

Detailed reference viewed: 44 (6 ULiège)
Full Text
See detailCA19.9 assays provide clinically different results for the patients
Schoneveld, Lauranne ULiege; LUKAS, Pierre ULiege; CAVALIER, Etienne ULiege et al

Poster (2020, November 20)

Detailed reference viewed: 54 (8 ULiège)
See detailCA19.9 assays provide clinically different results for the patients
Schoneveld, Lauranne ULiege; LUKAS, Pierre ULiege; CAVALIER, Etienne ULiege et al

Conference (2020, November 20)

Detailed reference viewed: 27 (7 ULiège)
Full Text
Peer Reviewed
See detailCould KL-6 levels in COVID-19 help to predict lung disease?
Frix, Anne-Noëlle ULiege; Schoneveld, Lauranne ULiege; LADANG, Aurélie ULiege et al

in Respiratory Research (2020), 21(309),

BACKGROUND: Coronavirus disease COVID-19 has become a public health emergency of international concern. Together with the quest for an effective treatment, the question of the post-infectious evolution of ... [more ▼]

BACKGROUND: Coronavirus disease COVID-19 has become a public health emergency of international concern. Together with the quest for an effective treatment, the question of the post-infectious evolution of affected patients in healing process remains uncertain. Krebs von den Lungen 6 (KL-6) is a high molecular weight mucin-like glycoprotein produced by type II pneumocytes and bronchial epithelial cells. Its production is raised during epithelial lesions and cellular regeneration. In COVID-19 infection, KL-6 serum levels could therefore be of interest for diagnosis, prognosis and therapeutic response evaluation. MATERIALS AND METHODS: Our study retrospectively compared KL-6 levels between a cohort of 83 COVID-19 infected patients and two other groups: healthy subjects (n = 70) on one hand, and a heterogenous group of patients suffering from interstitial lung diseases (n = 31; composed of 16 IPF, 4 sarcoidosis, 11 others) on the other hand. Demographical, clinical and laboratory indexes were collected. Our study aims to compare KL-6 levels between a COVID-19 population and healthy subjects or patients suffering from interstitial lung diseases (ILDs). Ultimately, we ought to determine whether KL-6 could be a marker of disease severity and bad prognosis. RESULTS: Our results showed that serum KL-6 levels in COVID-19 patients were increased compared to healthy subjects, but to a lesser extent than in patients suffering from ILD. Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease. DISCUSSION AND CONCLUSION: Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. Concerning the therapeutic response prediction, more studies are necessary. [less ▲]

Detailed reference viewed: 72 (20 ULiège)